Valuation: VISEN Pharmaceuticals

Market Cap 1.41B 1.66B 212M 189M 175M 158M 296M 20.11B 301M 2.1B 833M 10.54B 795M 778M 33.22B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 1.15B 1.35B 173M 154M 142M 129M 241M 16.38B 245M 1.71B 678M 8.58B 647M 634M 27.05B EV / Sales 2026 *
17x
EV / Sales 2027 * 4.42x
Free-Float
28.04%
Yield 2026 *
-
Yield 2027 * -
1 day-10.43%
1 week-17.62%
Current month-18.80%
1 month-19.79%
3 months-21.08%
6 months-38.96%
Current year-53.66%
1 week 15.1
Extreme 15.1
18.5
1 month 15.1
Extreme 15.1
19.9
Current year 15.1
Extreme 15.1
43.3
1 year 15.1
Extreme 15.1
43.3
3 years 15.1
Extreme 15.1
69.15
5 years 15.1
Extreme 15.1
69.15
10 years 15.1
Extreme 15.1
69.15
Manager TitleAgeSince
Chief Executive Officer 60 06/11/2018
Director of Finance/CFO 42 12/10/2025
Chief Tech/Sci/R&D Officer 54 31/03/2020
Director TitleAgeSince
Director/Board Member 60 06/11/2018
Director/Board Member 44 07/01/2021
Director/Board Member 62 31/03/2021
Date Insider Type Main position Quantity % Market Cap. Importance
01/01/26 Other

Chief Executive Officer

108,750 0.0955%
Change 5-day change 1-year change 3-year change Capi.($)
-10.43%-17.62%-62.75% - 212M
+2.41%+0.29%+42.02%+71.57% 64.69B
-0.15%+7.50%+11.01%+73.48% 54.78B
+0.57%+4.60%+10.07%+92.86% 53.49B
+0.37%+4.67%+27.03%+52.07% 45.98B
-1.21%+2.32%+21.80%+123.81% 42.94B
-0.37%+5.07%+249.91%+918.74% 40.08B
+0.05%+0.21%+18.26%+58.53% 33.52B
-0.38%+5.68%+36.43%+27.54% 23.67B
+1.19%-4.98%+29.01%-0.65% 23.97B
Average -0.79%+0.41%+38.28%+157.55% 38.33B
Weighted average by Cap. +0.38%+2.72%+47.51%+158.58%

Financials

2026 *2027 *
Net sales 67.73M 79.64M 10.15M 9.07M 8.38M 7.59M 14.2M 964M 14.44M 101M 39.91M 505M 38.11M 37.3M 1.59B 320M 376M 47.95M 42.82M 39.55M 35.84M 67.06M 4.55B 68.17M 476M 188M 2.38B 180M 176M 7.52B
Net income - -
Net Debt -262M -308M -39.33M -35.12M -32.44M -29.4M -55M -3.73B -55.91M -390M -155M -1.96B -148M -144M -6.17B 486K 571K 72.87K 65.07K 60.12K 54.48K 102K 6.92M 104K 723K 286K 3.62M 273K 268K 11.43M
Projected Income Statement - Annual - VISEN Pharmaceuticals
Logo VISEN Pharmaceuticals
Visen Pharmaceuticals is a holding company mainly engaged in developing and commercializing disruptive endocrine therapies. The Company's main products under development include lonapegsomatropin, navepegritide, and palopegteriparatide. The lonapegsomatropin is used to treat growth hormone deficiency in children aged 3 to 17 years old. The navepegritide is a disease repair therapy used to treat children with cartilage dysplasia aged 2 to 10 years old. The palopegteriparatide is a treatment method used to treat adult hypoparathyroidism. The Company is in the late stage of research and development, and its products are close to commercialization.
Employees
102
Date Price Change Volume
23/10/26 HK$15.20 -10.43% 66,400
22/10/26 HK$16.97 -1.96% 11,800
21/10/26 HK$17.31 -2.97% 10,900
20/10/26 HK$17.84 -3.31% 5,400
16/10/26 HK$18.45 +1.26% 6,000
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
12.93CNY
Average target price
42.85CNY
Spread / Average Target
+231.44%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - VISEN Pharmaceuticals
  1. Stock Market
  2. Stocks
  3. 2561 Stock